Navigation Links
A New Mechanism for Tau Protein Pathology in Alzheimer's Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting

NEW YORK, Nov. 16, 2011 /PRNewswire/ -- Oligomerix, Inc. presented results at the Society for Neuroscience meeting in Washington D.C. which demonstrated that tau protein forms neurotoxic oligomers with a newly discovered enzymatic function. This proteolytic function results in tau's self-fragmentation and in the degradation of other proteins suggesting a mechanism for its neurotoxic mode-of-action. Furthermore, certain tau oligomer species that contained the highest level of activity also proved to be the most toxic to cultured neurons. Tau's enzymatic activity may play a key role in Alzheimer's disease (AD) progression and therefore may represent an important therapeutic intervention point.

James Moe, President and CEO of Oligomerix, Inc., stated, "Recent advances in the field indicate that tau oligomers are involved in Alzheimer's disease progression and inhibit memory formation.  Inhibiting the tau oligomer protease may be an effective intervention for not only improving cognitive function, but also for interrupting disease progression."

The Alzheimer's Association estimates that there are 5.4 million AD sufferers in the US alone that require 14.9 million unpaid caregivers and costs the US economy approximately $183 billion every year.  There are no FDA approved therapeutics that alter the course of disease or slow its progression. Tau protease pathology may represent a new target for slowing or arresting disease progression.


Oligomerix, Inc. is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches, and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity.  The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.  The Company is seeking strategic partners to help accelerate its exciting tau protease program.

For more information visit

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

Oligomerix, Inc.
Jack Pasini
Chief Commercial Officer

Tiberend Strategic Advisors, Inc.
Andrew Mielach, Media

SOURCE Oligomerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Scripps Research team discovers treatable mechanism responsible for often deadly response to flu
2. Oxidation mechanisms at gold nanoclusters unraveled
3. New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
4. Finding a protective mechanism for retinal cells could save sight
5. Scientists use math modeling to predict unknown biological mechanism of regulation
6. Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
7. Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity
8. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
9. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
10. DNA duplication: A mechanism for survival of the fittest
11. New Insights into the Mechanism of Action of Antipsychotic Drugs
Post Your Comments:
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):